中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
22期
40-42
,共3页
消化道肿瘤%化疗前后%T淋巴细胞亚群
消化道腫瘤%化療前後%T淋巴細胞亞群
소화도종류%화료전후%T림파세포아군
Digestive tract tumor%Before and after chemotherapy%T-lymphocyte subsets
目的:探讨不同类型消化道肿瘤患者在化疗前后T细胞亚群总T细胞(CD3+)、T辅助淋巴细胞(CD4+)、T抑制淋巴细胞(CD8+)、CD4+/CD8+比值的变化情况及临床意义。方法应用流式细胞术分析不同类型消化道肿瘤患者在化疗前后及对照组CD3+、CD4+、CD8+细胞百分率和CD4+/CD8+比值。结果消化道肿瘤患者化疗前CD3+、CD4+、CD4+/CD8+比例均低于对照组,CD8+高于对照组,差异均有统计学意义(P<0.05);结肠癌和胃癌患者化疗后CD3+、CD4+百分比较化疗前均增高,CD8+百分比降低,差异均有统计学意义(P<0.05)。直肠癌患者化疗后CD3+百分比较化疗前增高,CD8+百分比降低,差异有统计学意义(P<0.05),CD4+、CD4+/CD8+比值差异无统计学意义(P>0.05)。结论通过检测消化道肿瘤患者T淋巴细胞亚群化疗前后的变化,对了解机体的免疫动态有着重要的临床意义。
目的:探討不同類型消化道腫瘤患者在化療前後T細胞亞群總T細胞(CD3+)、T輔助淋巴細胞(CD4+)、T抑製淋巴細胞(CD8+)、CD4+/CD8+比值的變化情況及臨床意義。方法應用流式細胞術分析不同類型消化道腫瘤患者在化療前後及對照組CD3+、CD4+、CD8+細胞百分率和CD4+/CD8+比值。結果消化道腫瘤患者化療前CD3+、CD4+、CD4+/CD8+比例均低于對照組,CD8+高于對照組,差異均有統計學意義(P<0.05);結腸癌和胃癌患者化療後CD3+、CD4+百分比較化療前均增高,CD8+百分比降低,差異均有統計學意義(P<0.05)。直腸癌患者化療後CD3+百分比較化療前增高,CD8+百分比降低,差異有統計學意義(P<0.05),CD4+、CD4+/CD8+比值差異無統計學意義(P>0.05)。結論通過檢測消化道腫瘤患者T淋巴細胞亞群化療前後的變化,對瞭解機體的免疫動態有著重要的臨床意義。
목적:탐토불동류형소화도종류환자재화료전후T세포아군총T세포(CD3+)、T보조림파세포(CD4+)、T억제림파세포(CD8+)、CD4+/CD8+비치적변화정황급림상의의。방법응용류식세포술분석불동류형소화도종류환자재화료전후급대조조CD3+、CD4+、CD8+세포백분솔화CD4+/CD8+비치。결과소화도종류환자화료전CD3+、CD4+、CD4+/CD8+비례균저우대조조,CD8+고우대조조,차이균유통계학의의(P<0.05);결장암화위암환자화료후CD3+、CD4+백분비교화료전균증고,CD8+백분비강저,차이균유통계학의의(P<0.05)。직장암환자화료후CD3+백분비교화료전증고,CD8+백분비강저,차이유통계학의의(P<0.05),CD4+、CD4+/CD8+비치차이무통계학의의(P>0.05)。결론통과검측소화도종류환자T림파세포아군화료전후적변화,대료해궤체적면역동태유착중요적림상의의。
Objective To investigate the T cell subsets (CD3+) T cells, T lymphocytes (CD4+), T lymphocytes (CD8+) and CD4+/CD8+ratio digestive tract tumor before and after chemotherapy changes and clinical significance of patients with digestive tract tumor before and after chemotherapy. Methods Flow cytometry was used to analyze the CD3+, CD4+, CD8+cell percentage and the ratio of CD4+/CD8+ in different types of gastrointestinal cancer patients before and after chemotherapy and the healthy (control group). Results Compared with the control group, the former chemotherapy CD3+, CD4+, CD4+/CD8+ratio of gastrointestinal cancer patients were lower than that of control group (P< 0.05), and CD8+was higher than the control group (P<0.05), the differences were statistically significant. Colon cancer and stom-ach cancer patients after chemotherapy CD3+, CD4+percentages were higher than before chemotherapy (P<0.05), the percentage of CD8+was lower (P< 0.05), the differences were statistically significant. Patients with rectal cancer after chemotherapy CD3+percentage was higher before chemotherapy (P<0.05), the percentage of CD8+was lower (P<0. 05), the differences were statistically significant; while CD4+and CD4+/CD8+ratio had no statistical significance (P>0.05). Conclusion For the digestive tract tumor, detecting the changes of T lymphocyte subsets to understand the im-mune dynamic, in determining the clinical curative effect, and assess the prognosis monitoring, etc., all have very im-portant clinical significance.